Amy's strategic approach to intangible asset protection often results in tangible value to client businesses. By understanding the science behind innovations and their commercial potential, she creates tailored exclusivity profiles that align with commercial objectives. This unique perspective allows her to ask critical questions others might overlook. Having had the privilege to support Nobel, NCI, Burger, and Kettering award winners in medicinal chemistry research, Amy welcomes the opportunity to play a role in advancing innovation.

In the fast-paced world of drug development, Amy is skilled at managing global patent portfolios across diverse therapeutic areas. She drafts applications for new chemical entities and supporting portfolio inventions; conducts due diligence for licensing and acquisitions, including blinded diligence review to maintain confidentiality; and provides important freedom-to-operate analyses and landscape support for innovator companies.

Beyond patents, Amy helps clients navigate the complex regulatory landscape surrounding pharmaceuticals, biologics, and medical devices. She coordinates patent and regulatory exclusivities, supports in-house teams through FDA approval processes, and develops strategies for Hatch-Waxman patent term extensions with a focus on ensuring clients maximize their market position.